Loading stock data…
Spero Therapeutics (SPRO)
$2.26
Market ClosedLast close Jun 29
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Spero Therapeutics, Inc. in the Healthcare sector is trading at $2.26 with a market capitalization of $162M. Wall Street consensus targets $4.00 (1 analysts), implying a +77.0% move over the next 12 months. The stock is currently 30% below its 52-week high of $3.22, remaining 5.8% below its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality. Risk note: MACD remains below its signal line. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +77.0% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $258,000↓ | $39.66M↑ | $3.05M↓ | $11.80M↑ | $5.11M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$7.54M↓ | $31.41M↑ | -$7.33M↓ | -$2.36M↑ | -$14.56M |
| Net Income | -$7.20M↓ | $31.52M↑ | -$7.38M↓ | -$1.70M↑ | -$13.87M |
Peer Comparison
JNJUNHPFE
Fundamentals
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$162.41M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
28.78%
Volume
Today's trading volume
517,226
Recent News
GSK (LSE:GSK) Wins FDA Approval For Utebzi As Momelotinib Gains Orphan Tag
GSK (LSE:GSK) and Spero Therapeutics received U.S. FDA approval for Utebzi, a first in class oral carbapenem antibiotic for complicated urinary tract infections. Utebzi offers an oral treatment option where patients have often relied on intravenous antibiotics for multi drug resistant infections. The U.S. FDA also granted Orphan Drug Designation to GSK's momelotinib for treating VEXAS syndrome, a rare blood disorder. For investors tracking GSK, these two regulatory milestones highlight the...
Is GSK plc (GSK) Expanding Its Anti-Infectives Leadership With New FDA-Approved Therapy?
We recently compiled a list of the 10 Best Weight Loss Drug Stocks to Buy in 2026. GSK plc (NYSE:GSK) is one of the best weight loss drugs on this list. TheFly reported on June 17 that GSK and Spero Therapeutics announced that the U.S. Food and Drug Administration approved Utebzi for the treatment of complicated urinary tract infections, including […]
GSK, Spero Win FDA Nod For First-Ever Oral Carbapenem Antibiotic For Complicated UTIs
GSK plc and Spero Therapeutics, Inc. announced on Wednesday that the U.S. Food and Drug Administration has approved Utebzi (tebipenem pivoxil hydrobromide), an oral antibiotic for adults with complicated urinary tract infections (cUTIs). First Oral Carbapenem Approved For This Patient Population The indication includes pyelonephritis, caused by certain susceptible pathogens, and patients who have limited or no alternative oral treatment options. The companies said Utebzi is the first and only or
Spero Shares Jump After FDA Clears First Oral Carbapenem Antibiotic for U.S. Market (SPRO)
Spero Therapeutics (NASDAQ:SPRO) shares climbed 16% on Thursday after the U. S.
Promising Penny Stocks To Consider In May 2026
The United States market has shown impressive growth, with a 1.1% increase over the last week and a substantial 27% rise over the past year, alongside expectations for earnings to grow by 17% annually in the coming years. Penny stocks, while an older term, continue to capture attention as they often represent smaller or newer companies that provide growth opportunities at lower price points. By focusing on those with strong financial health and solid fundamentals, investors can uncover...